Abstract
Background/Aim. Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) 2019 infection represents a global problem. At this moment, in October 2020, there is no vaccine or efficient treatment for infected patients. Treatment with blood plasma rich with anti-SARS-CoV-2 specific antibodies might be a safe, and effective therapy for COVID-19 patients. Methods. A total of 768 patients were analyzed in this study, whose samples were collected in a time interval from May 1, 2020, till August 15, 2020. Patients were enrolled in the study from COVID-19 hospitals and out-clinics. In-house ELISA tests were developed to measure the concentration of anti-S1S2 spike and anti-nucleoprotein (np) (IgG, IgA, IgM) SARS-CoV-2 antibodies. Blood convalescent plasma was selectively collected from recovered patients according to specific antibodies concentration. Results. The highest concentrations of anti-S1S2 spike or anti-np specific IgG antibodies were detected in patients with the moderate/heavy clinical form of the infection. An extremely high concentration of anti-S1S2 spike IgG and anti-np IgG was demonstrated in 3% and 6% of patients who recovered from severe COVID-19, respectively. Of tested hospitalized patients, 63% and 51% had modest levels of anti-S1S2 spike and anti-np, respectively. After 60 days, in our selected donors, concentrations of anti-S1S2 spike IgG and anti-np IgG antibodies increased in 67% and 58% of donors, respectively. Conclusion. In-house developed ELISA tests enable a novel protocol for selecting convalescent blood plasma donors recovered from SARS-CoV-2 infection.
Keywords
clinical protocols
covid-19 serotherapy
enzyme-linked immunosorbent assay
SARS-CoV-2
plasma
tissue donors
References
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 324(8): 782‒93.
Park A. Blood Plasma Treatment for Coronavirus Set to Get Its First Trial Run in New York. Available from: https://time.com/5809955/blood-plasma-coronavirus/[cited 2020 March 26]
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convales-cent Plasma. JAMA 2020; 323(16): 1582‒9.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improve-ment in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020; 324(5): 460‒70.
Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Oster-haus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020; 11(1): 2251.
Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020; 369(6504): 643‒50.
Food and Drug Administration. Coronavirus disease 2019 (COVID-19) EUA nformation. 2020. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/ emer-gency-use-authorization#covid19euas. [accessed 2020 August 31].
Grady D. Blood Plasma From Survivors Will Be Given to Coronavirus Patients. Available from: www.nytimes.com › health › plasma [updated 2020 August 4].
The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Convalescent Plasma for the Treatment of COVID-19. Available from: https://www.covid19treatmentguidelines.nih.gov/ [updated 2020 September 1]
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Es-timation and Application. Ann Intern Med 2020; 172(9): 577‒82.
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profil-ing Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020; 71(15): 778‒85.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Corona-virus Disease 2019. Clin Infect Dis 2020; 71(16): 2027‒34.
National Institutes of Health website. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available from: https://www.covid19treatmentguidelines.nih.gov/ [accessed 2020 July 1].
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 conva-lescent plasma in 5000 patients. J Clin Invest 2020; 130(9): 4791‒7.
U.S. Food and Drug Administration. Convalescent plasma let-ter of authorization. Available from: https://www.fda.gov
/media/141477/download. [accessed 2020 August 31].
U.S. Food and Drug Administration. EUA 26382: Emergency Use Authorization (EUA) Request. Available from: www.fda.gov/media/141481/download [accessed 2020 Sep-tember 6].
Edwards T , Semple MG , De Weggheleire A , Claeys Y , De Crop M, Menten J et al. Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treat-ment of Ebola virus disease in Guinea during the 2014–2015 outbreak. ClinTrials 2016; 13(1):13–21.
Choi JY. Convalescent Plasma Therapy for Coronavirus Dis-ease 2019. Infect Chemother 2020; 52(3): 307‒16.
Convalescent Plasma Collection Program. Available from: health.mil › Coronavirus › COVID. [accessed 2020 September 29]
Yiğenoğlu TN, Hacıbekiroğlu T, Berber I, Dal MS, Baştürk A, Namdaroğlu S. Convalescent plasma therapy in patients with COVID‐19. J Clin Apher 2020; 35(4): 367‒73.
Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; 92(9): 1518‒24.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu Y, et al. The Feasibil-ity of Convalescent Plasma Therapy in Severe COVID‐19 Pa-tients:a Pilot Study. medRxiv 2020; doi: 10.1101/2020.03.16.20036145.
Casadevall A, Scharff MD. Return to the past: the case for an-tibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21(1): 150‒61.
Casadevall A. Passive antibody administration (immediate im-munity) as a specific defense against biological weapons. Emerg Infect Dis 2002; 8(8): 833‒41.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 324(8):782−93.